PCM
KALV

Pentwater Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Pentwater Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8,161
Closed -$408K – 124
2015
Q3 		$408K Sell
8,161
-7,910
-49% -$674K ﹤0.01% 124
2015
Q2 		$1.61M Buy
+16,071
New +$1.59M 0.01% 147

Other funds holding KALV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Pentwater Capital Management's KALV Position: Q4 2015 in Review

Pentwater Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2015, closing a stake of 8,161 shares — an estimated $408K sold.

Pentwater Capital Management first reported a position in KALV in Q2 2015 and held it in 2 quarters. The position peaked at $1.61M in Q2 2015. 47 funds tracked by Wall St. Rank hold KALV as of Q4 2015.

  • Pentwater Capital Management reported no remaining KalVista Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Pentwater Capital Management sold 8,161 KalVista Pharmaceuticals shares in Q4 2015, an estimated $408K.
  • Pentwater Capital Management first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Pentwater Capital Management's KalVista Pharmaceuticals position peaked at $1.61M in Q2 2015.
  • 47 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2015.

Based on Pentwater Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.